Results 131 to 140 of about 51,398 (196)
Abdominal Crisis in the Malignant Carcinoid Syndrome
Archives of Internal Medicine, 1966 EPISODES of acute abdominal pain during the course of the malignant carcinoid syndrome often present a major challenge to physicians caring for patients with this unique disease. The primary tumor (usually in the small intestine) rarely causes symptoms until widespread metastases occur.
C. E. Mengel
+6 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Malignant Carcinoid Syndrome Associated with Noncarcinoid Tumors
New England Journal of Medicine, 1965DURING the past decade the "malignant carcinid syndrome" has been a favored subject in the medical literature because of the dramatic nature of its acute and chronic clinical manifestations and of its as yet unresolved challenges to the physiologist and therapist.
Oliver H. Beahrs +3 more
openaire +3 more sources
Treatment of the Malignant Carcinoid Syndrome
Survey of Anesthesiology, 1986We studied the effects of a long-acting analogue of somatostatin (SMS 201-995, Sandoz) in 25 patients with histologically proved metastatic carcinoid tumors and the carcinoid syndrome. This drug was self-administered by subcutaneous injection at a dose of 150 micrograms three times daily. Flushing and diarrhea associated with the syndrome were promptly
Joseph Rubin +5 more
openaire +5 more sources
Diagnosis and Treatment of Malignant Carcinoid Syndrome
JAMA: The Journal of the American Medical Association, 1975 To the Editor.— The article, "Diagnosis and Treatment of Malignant Carcinoid Syndrome," by Dr. A. L. Ureles (229:1346, 1974) contains several serious errors. In this letter I shall concentrate on those that have substantial patient-care implications. Documentation of the statements I shall make may be found in a recent textbook chapter1that will also ...
Robert J. Levine
openaire +3 more sources
Cutaneous Manifestations of the Malignant Carcinoid Syndrome
Annals of Internal Medicine, 1963 Charles E. Mengel
semanticscholar +4 more sources
Treatment of Malignant Carcinoid Syndrome With a Long-Acting Somatostatin Analogue
Archives of Dermatology, 1989A patient with malignant carcinoid syndrome was treated with a long-acting somatostatin analogue. The cutaneous and systemic improvement our patient had while receiving this therapy is described.
Jaime A. Tschen +2 more
openaire +4 more sources
Archives of Internal Medicine, 1966 SINCE the early descriptions of the carcinoid syndrome, 1-4 it has been assumed that the associated hyperserotonemia is responsible for the symptoms and development of the cardiac lesions. These lesions, which appear mainly on the right side of the heart, are characterized by subendocardial proliferation of fibrous tissue resulting in thickening of the
Arnold Adicoff +2 more
openaire +4 more sources
Cushing's and Malignant Carcinoid Syndromes From Ovarian Neoplasm
Archives of Internal Medicine, 1965 Introduction THERE is a growing appreciation of the protean nature of the so-called carcinoid tumor in terms of site of origin, histological appearance, and capacity for hormone production. 1 In addition to the now widely recognized capacity of these tumors to produce the tryptophan metabolite, serotonin (5-HT), and the serotonin precursor, 5 ...
Montague Lane, Harold Brown
openaire +4 more sources
Malignant carcinoid syndrome: Survival in the octreotide LAR era
Journal of Clinical Oncology, 2005 4084 Background: Somatostatin analogues (SMSA) (octreotide) are effective in controlling excess hormonal symptoms in the majority of patients (pts) with carcinoid syndrome.
Y. Shyr, L. B. Anthony, T. Kang
openaire +3 more sources
The malignant carcinoid syndrome
The American Journal of Digestive Diseases, 1966R. J. Gailitis
openaire +4 more sources